Taro Yamanaka, Medical Oncologist at National Cancer Center Hospital, Japan, shared a post on X:
“Big news for HER2+ MBC!
DESTINY-Breast09 T-DXd + pertuzumab significantly improved PFS vs. THP in 1L setting.
OS data still maturing, but early trends look promising.
Detailed results to follow—future updates will be key.”